A multicultural group practicing yoga together in a bright studio

Best Alternatives to Henry Meds for GLP-1 (2026): Verified Prices

Verified Henry Meds alternatives: Embody $69/mo promo, Sprout $149, TMates $158 with faster shipping, plus where Henry still wins on documentation.

By RangeYourselfUpdated August 21, 20264 min read

Editorial + affiliate disclosure. RangeYourself may earn a commission when you book or buy through links on this page (marked with the /go/ prefix). It costs you nothing extra and does not influence our rankings. Where programs are exactly tied on price and every factor we track, we list programs that support the site first, and we label the tie. Pricing and program details verified September 2026 from each provider’s public pages; verify current terms before you purchase. See how we verify pricing and provider claims.

Quick Answer

The strongest verified alternatives to Henry Meds right now: Embody GLP-1 is the cheapest at $69/mo (limited-time promo, verified 2026-09-17) (confirm at checkout). Sprout Health follows from $149/mo, then TMates ($158/mo with promotion, plus faster shipping). Henry Meds itself starts at $179/month, verified July 9, 2026, three of these alternatives are meaningfully cheaper. (Direct Meds’ sublingual, briefly level with Henry at $179.10/mo under a 10%-off rate, reverted to $249/mo (sublingual all-inclusive rate, verified 2026-07-25) on its own product page and now costs meaningfully more than Henry.) (A few programs RY tracks go lower still, Strut Health’s sublingual from $99/mo, bmiMD from $99/mo on a 12-month plan, and Trimi at $99/mo billed annually, but each carries a format or commitment tradeoff; see the GLP-1 Price Index.)

People usually look for a Henry Meds alternative for one of four reasons: a lower price, faster first shipment (Henry’s typically arrives 8–10 business days after the provider visit), a different medication format, or a brand-name/insurance path Henry doesn’t focus on. Here’s the honest map.

Every price was read from the provider’s live site on the date shown. Promotional rates are flagged. Confirm current rates at signup.

Verified Alternatives, Ranked by Entry Price

Program	Entry price (compounded semaglutide)	Strongest reason to pick it over Henry	Verified
Embody GLP-1	$69/mo (limited-time promo, verified 2026-09-17)	Now the lowest entry price here; same price every dose. Not available in MS or LA	Aug 21, 2026
Sprout Health	From $149/mo (starting dose)	Mid-market price with clinician access; brand-name Wegovy/Zepbound also listed cash-pay	Jul 3, 2026
TMates	$158/mo (with $100-off promotion)	Cheaper than Henry at entry + advertised free 1–2 day shipping vs Henry’s 8–10 business days	Jul 9, 2026
Mochi Health	$79/mo membership + $99/mo medication (~$178)	Insurance path to brand-name Wegovy/Zepbound. Henry is compounded-focused	Jul 3, 2026
Direct Meds	From $249/mo (sublingual)	Sublingual format; multiple formats, no longer at Henry’s price level. Not available in LA	2026-07-25

Where Henry Meds Still Wins

An honest alternatives page has to say this: Henry Meds (verified July 9, 2026) remains one of the strongest programs in the category on documentation and track record. It publishes its pharmacy sourcing (503A compounding pharmacies and 503B outsourcing facilities), cites a published retrospective study of its own patients (Rubio et al., 2025: ~18% average body-weight loss over a year on injectable semaglutide, company-connected research, disclosed as such), and posts detailed program terms. If those things matter more to you than $20–$30/month, staying put is a defensible choice, see our full Henry Meds review and TMates vs Henry Meds head-to-head.

One Henry-specific caution that sends people shopping: cancel-anytime applies cleanly to monthly plans, but multi-month plans may require paying out the remaining balance. If flexibility matters, compare monthly-only terms, TMates and Embody both advertise no-membership, cancel-anytime structures.

How to Choose

Price is the reason you’re leaving: Embody ($69/mo), or Sprout Health ($149), or TMates ($158 with promotion)
Shipping speed: TMates, advertised 1–2 days vs Henry’s 8–10 business days
You want an insurance/brand-name path: Mochi Health, or see Sprout vs Ro for the full brand-name model
Full market view: the GLP-1 Price Index, every program we track, verified and dated

Safety note on compounded GLP-1 medications: Henry Meds and the alternatives above prescribe compounded GLP-1 medications, which are not FDA-approved finished drug products and are not reviewed by the FDA for safety, effectiveness, or quality before sale. No GLP-1 medication should be used without a prescription from a licensed clinician. GLP-1 medications are not appropriate for everyone, including, per FDA labeling for semaglutide and tirzepatide, people with a personal or family history of medullary thyroid carcinoma or MEN2, and side effects can include nausea, vomiting, diarrhea, constipation, abdominal pain, and dehydration.

FAQ

What’s the cheapest alternative to Henry Meds?

At current verified rates, Embody GLP-1 is the cheapest at $69/mo (limited-time promo, verified 2026-09-17). That’s well under Henry’s $179 entry; Sprout Health follows at $149/month. Embody’s price is a limited-time promotion that has moved before, so confirm the post-promotional rate before enrolling. A few programs RY tracks go lower still, Strut Health’s sublingual from $99/mo, bmiMD from $99/mo on a 12-month plan, and Trimi at $99/mo billed annually, each with a format or commitment tradeoff.

Which alternative ships fastest?

TMates advertises free 1–2 day delivery. Henry Meds states most patients receive medication 8–10 business days after their provider visit.

Is any alternative better if I have insurance?

Henry and most of these alternatives are cash-pay compounded programs. If your insurance may cover brand-name Wegovy or Zepbound, Mochi Health’s membership model pursues that, and Ro builds its whole program around it.

Can any of these programs guarantee a prescription?

No. Every legitimate program uses licensed clinicians who prescribe only when treatment is clinically appropriate. A guaranteed prescription is a red flag.

RangeYourself may earn a commission if you sign up through links on this page, see how we make money. Rankings are based on verified pricing and program structure, never on commissions. Prices change frequently, always confirm current rates on each provider’s website before purchasing.

About compounded GLP-1 medicationsCompounded semaglutide and tirzepatide are not FDA-approved finished products. They are prepared by state-licensed 503A pharmacies or 503B outsourcing facilities and are not individually reviewed by the FDA for safety, effectiveness, or quality. Compounders describe these preparations as using the same active ingredient as the approved medicines; the FDA has warned that some compounded products use salt forms, semaglutide sodium or semaglutide acetate, that it considers different active ingredients from the approved drug, and has issued warning letters over marketing that presents a compounded preparation as interchangeable with an approved one. The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so the shortage-era pathway for broad compounding of these drugs has ended. Compounding now proceeds under the ordinary rules: a 503A pharmacy compounding for an individual patient on a prescription, or a 503B outsourcing facility, which compounds in bulk under CGMP and FDA registration rather than per patient. Those rules generally do not cover a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for an individual patient. Talk to a clinician about contraindications including personal or family history of medullary thyroid carcinoma or MEN 2. RangeYourself does not provide medical advice, does not guarantee a prescription, and does not guarantee weight-loss results.

RangeYourself is reader-supported. We may earn a commission when you click on certain links, at no extra cost to you. Editorial recommendations are made independently. Content last updated August 21, 2026.